☰

NextCellPharma

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of NextCellPharma's published strategy and is not endorsed by, or produced in cooperation with, NextCellPharma. Company website

Strategic priorities

NextCellPharma operates across 4 stated priorities, with the most concrete near-term plan anchored on phase iii clinical advancement.

Driving ProTrans-Young and ProTrans-Adult clinical trials toward regulatory approval, targeting Type 1 Diabetes treatment with allogeneic MSC therapy through structured partnerships in Europe and Asia.

Building Scandinavia's one-stop-shop for ATMP quality control services including sterility, potency, and identity testing, with strategic partnerships including bioMerieux and SKAN.

Establishing Hong Kong as a gateway to the Chinese market for ProTrans adult trials, with pre-studies conducted throughout 2025 to navigate regulatory divergence.

Challenges we see

  • Operations Manufacturing

    Manufacturing Scalability Gap

    NextCell faces the classic academic-to-commercial bottleneck as MSC manufacturing remains labor-intensive and manual, requiring real-time monitoring of chemical and physical parameters currently tracked in silos or manually.

    Scaling up production for Phase III without durable automation tools risks inconsistent product quality and regulatory rejection, as agencies view manufacturing process as part of the drug itself.

  • Digital Integration

    Digital Data Fragmentation

    Despite having a Digital Twin for NextCell Lab (via DCC partnership), day-to-day operations rely on legacy workflows with sophisticated hardware operating as "islands of automation" where data is trapped in local historians.

    Manual transcription from flow cytometers, SKAN isolators, and bioMerieux tools into Excel sheets drives data integrity risks and prevents proactive process control.

  • Operations Manufacturing

    Multi-Site Manufacturing Disconnect

    The split between internal Grade D research manufacturing in Stockholm and clinical-grade production in Poland (PBKM) creates a "Digital Nervous System" gap with SOPs and batch records managed across two organizations.

    Data fragmentation between geographically dispersed manufacturing sites introduces compliance risks and slows process optimization for the critical ProTrans production.

  • Compliance Regulatory

    Regulatory Compliance Burden

    International expansion into Hong Kong/China requires navigating divergent regulatory environments while maintaining EU GMP compliance and preparing for NIS 2 Directive cybersecurity requirements.

    The decentralized international model expands the attack surface while small teams face steep validation complexity that slows innovation and drains management bandwidth.

  • Operations Operations

    Cold Chain and Supply Chain Sensitivity

    MSC products are thermally and time-sensitive, with any transport delay potentially causing total batch loss costing up to $100,000 per treatment, requiring Chain of Identity visibility.

    Reliance on third-party logistics through Royale International partnership without integrated digital tracking drives risks of batch loss and compliance gaps in product traceability.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Digital Twin Under-Utilization

    NextCell's existing Digital Twin (via DCC partnership) is currently limited to training and simulation rather than real-time process control, leaving significant value unrealized from the digital investment.

    Connect the Digital Twin to live sensors via OPC UA/MQTT protocols to enable predictive bioprocess insights and move from post-experiment analysis to proactive process optimization.

  2. QVance Manual Lab Workflows

    QVance aims to be a one-stop-shop for ATMP analytics but operates with paper-based SOPs and manual data capture from flow cytometers, limiting scalability and creating data integrity risks.

    Transform QVance into a Digital-First Lab with an Industrial Data Platform enabling real-time sample tracking and automated result capture, shifting from service-for-hire to platform-as-a-service model.

  3. Manufacturing Process Validation

    Staff reduction initiatives signal a shift toward automation, but the completed Huddinge GMP facility lacks fully integrated digital infrastructure to support automated manufacturing validation.

    Implement Golden Batch profiles and validated automation systems that maintain product quality while reducing manual labor dependency and supporting regulatory approval for process changes.

  4. Cross-Border Data Governance

    Expansion into Hong Kong/China requires GAMP5-compliant cloud infrastructure for clinical trial data management across jurisdictions with different regulatory requirements.

    Implement secure, validated cloud architecture that enables smooth data sharing between Stockholm headquarters and Hong Kong operations while maintaining compliance across all jurisdictions.

  5. Gowning and Facility Flow Bottlenecks

    Small-scale GMP facilities like Huddinge face throughput restrictions when gowning areas accommodate only 2-3 operators at 20 minutes each, creating production capacity constraints.

    Deploy computer vision and facility flow optimization solutions to identify bottlenecks, optimize personnel movement, and maximize cleanroom utilization without physical expansion.

What we'd propose

  • Digital Lab

    Digital Lab Transformation for QVance

    End-to-end digitalization of QVance laboratory operations, replacing paper-based workflows with integrated digital systems for automated data capture, real-time sample tracking, and GxP-compliant analytics.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Production-Grade Digital Twin Implementation

    Evolution of existing training-focused Digital Twin into a production-grade system with live telemetry integration from cleanroom instruments enabling real-time process monitoring and predictive analytics.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    IT/OT Integration for Multi-Site Manufacturing

    Unified digital infrastructure connecting Stockholm and Poland (PBKM) manufacturing operations with standardized data collection, SOP management, and batch record synchronization across sites.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    GxP-Compliant Cloud Infrastructure for Asia Expansion

    Secure, GAMP5-validated cloud architecture supporting clinical trial data management across EU and Hong Kong jurisdictions with appropriate data residency and access controls.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Facility Flow Optimization System

    Computer vision and IoT-based monitoring system for cleanroom facility optimization, identifying personnel movement bottlenecks and maximizing throughput without physical infrastructure changes.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what NextCellPharma's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 35 → 80
Digital Twin exists for training but lacks live sensor integration; equipment operates as isolated automation islands.
Process Automation 30 → 75
Manufacturing remains labor-intensive with recent staff reductions signaling need for automation; minimal closed-loop control.
Analytics & Intelligence 40 → 85
Sophisticated hardware deployed but insights locked in Excel and local historians; no real-time predictive capabilities.
Regulatory Compliance Systems 45 → 80
Paper-based SOPs at QVance create ALCOA+ risks; NIS 2 compliance requirements increasing cybersecurity burden.
Cross-Site Connectivity 25 → 70
Stockholm-Poland manufacturing split creates Digital Nervous System gap; no unified batch record management.
Cloud & Security Infrastructure 30 → 75
International expansion to Hong Kong requires GAMP5-compliant cloud; current decentralized model increases attack surface.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with NextCellPharma, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].